Clinical Trials Browser

Phase 3 × Lung Neoplasms × tremelimumab × Clear all

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma